Xisheng Li1,2, Lidong Ning3, Qingmei Zhang4,5, Yingying Ge4,5, Chang Liu3, Shuiqing Bi3, Xia Zeng3, Weixia Nong4, Song Wu3, Gaoshui Guo3, Shaowen Xiao3, Bin Luo4,5, Xiaoxun Xie4,5,6. 1. Department of Neurosurgery, The People's Hospital of Guangxi Zhuang Autonomous Region China. 2. Laboratory of Multidisciplinary Treatment and Clinical Translation of Central Nervous System Tumors, The People's Hospital of Guangxi Zhuang Autonomous Region China. 3. Department of Neurosurgery, The First Affiliated Hospital of Guangxi Medical University China. 4. Department of Histology and Embryology, School of Pre-clinical Medicine, Guangxi Medical University China. 5. Guangxi Colleges and Universities Key Laboratory Research of Preclinical Medicine, Guangxi Medical University China. 6. Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education China.
Abstract
BACKGROUND: Cancer/testis antigens (CTAs) are attractive therapeutic targets for tumor immunotherapy due to their restrictive expression in normal testis but excessive in majority of tumor types. ACTL8, CTCFL, OIP5 and XAGE3 are members of the CTAs family. Currently, the data of ACTL8, CTCFL, OIP5 and XAGE3 expression in glioma is limited. Methods: ACTL8, CTCFL, OIP5 and XAGE3 mRAN and protein expressions were detected in 108 glioma samples by Reverse Transcriptase-PCR (RT-PCR) and immunohistochemistry and the correlations between their expressions and clinical indexes were analyzed. Furthermore, their clinical significance on glioma prognosis was determined by follow-up data. Results: The mRNA positive rate of ACTL8, CTCFL, OIP5 and XAGE3 was 15.74% (17/108), 22.22% (24/108), 13.89% (15/108) and 37.96% (41/108), respectively. At least one CTA mRNA was expressed by 61.11% of glioma tissues, while 2 or more by 29.63%. For protein expression, the positive rate of them was 21.30% (23/108), 34.26% (37/108), 19.44% (21/108) and 23.15% (25/108), respectively. At least one CTA protein was expressed by 58.33% of glioma tissues and 2 or more by 29.63%. Although there were no correlations between their mRNA expressions and clinicopathological parameters, the protein expression of ACTL8, OIP5 and XAGE3 was positively correlated with KPS; while the ACTL8 protein was correlated with gender, and OIP5 protein with gender and WHO grade. Kaplan-Meier analysis revealed a significant negative correlation between the CTCFL protein expression, combined ACTL8 and/or CTCFL protein expression and survival. Conclusions: The results suggest that the cohort of glioma does express ACTL8, CTCFL, OIP5 and XAGE3 at both mRNA and protein levels indicating glioma is CTAs-rich tumors. CTCFL protein and the combined ACTL8 and/or CTCFL protein might act as poor prognostic markers for glioma and as potential ideal combined antigens for glioma immunotherapy. AJTR
BACKGROUND:Cancer/testis antigens (CTAs) are attractive therapeutic targets for tumor immunotherapy due to their restrictive expression in normal testis but excessive in majority of tumor types. ACTL8, CTCFL, OIP5 and XAGE3 are members of the CTAs family. Currently, the data of ACTL8, CTCFL, OIP5 and XAGE3 expression in glioma is limited. Methods:ACTL8, CTCFL, OIP5 and XAGE3 mRAN and protein expressions were detected in 108 glioma samples by Reverse Transcriptase-PCR (RT-PCR) and immunohistochemistry and the correlations between their expressions and clinical indexes were analyzed. Furthermore, their clinical significance on glioma prognosis was determined by follow-up data. Results: The mRNA positive rate of ACTL8, CTCFL, OIP5 and XAGE3 was 15.74% (17/108), 22.22% (24/108), 13.89% (15/108) and 37.96% (41/108), respectively. At least one CTA mRNA was expressed by 61.11% of glioma tissues, while 2 or more by 29.63%. For protein expression, the positive rate of them was 21.30% (23/108), 34.26% (37/108), 19.44% (21/108) and 23.15% (25/108), respectively. At least one CTA protein was expressed by 58.33% of glioma tissues and 2 or more by 29.63%. Although there were no correlations between their mRNA expressions and clinicopathological parameters, the protein expression of ACTL8, OIP5 and XAGE3 was positively correlated with KPS; while the ACTL8 protein was correlated with gender, and OIP5 protein with gender and WHO grade. Kaplan-Meier analysis revealed a significant negative correlation between the CTCFL protein expression, combined ACTL8 and/or CTCFL protein expression and survival. Conclusions: The results suggest that the cohort of glioma does express ACTL8, CTCFL, OIP5 and XAGE3 at both mRNA and protein levels indicating glioma is CTAs-rich tumors. CTCFL protein and the combined ACTL8 and/or CTCFL protein might act as poor prognostic markers for glioma and as potential ideal combined antigens for glioma immunotherapy. AJTR
Authors: Morgan G Mathieu; Adam J Linley; Stephen P Reeder; Cécile Badoual; Eric Tartour; Robert C Rees; Stéphanie E B McArdle Journal: Cancer Immun Date: 2010-01-11
Authors: Catherine Barrow; Judy Browning; Duncan MacGregor; Ian D Davis; Sue Sturrock; Achim A Jungbluth; Jonathan Cebon Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: Betsy A Kohler; Elizabeth Ward; Bridget J McCarthy; Maria J Schymura; Lynn A G Ries; Christie Eheman; Ahmedin Jemal; Robert N Anderson; Umed A Ajani; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2011-03-31 Impact factor: 13.506
Authors: Marianna A Zolotovskaia; Max A Kovalenko; Victor S Tkachev; Alexander M Simonov; Maxim I Sorokin; Ella Kim; Denis V Kuzmin; Betul Karademir-Yilmaz; Anton A Buzdin Journal: Int J Mol Sci Date: 2022-06-30 Impact factor: 6.208